ANL Latest Press Releases

-- October 15, 2026 --

Adlai Nortye Enters into Clinical Collaboration with Lilly and Merck KGaA, Darmstadt, Germany to Evaluate Combination of AN4035 and Cetuximab Globe Newswire 7:00 AM

-- September 30, 2026 --

Adlai Nortye Appoints Christopher Liu, PharmD, as Head of Investor Relations and Public Relations Globe Newswire 7:00 AM

-- September 8, 2026 --

Adlai Nortye Announces First Patient Dosed in Australia and U.S. FDA IND Clearance for AN4035, a First-in-Class Pan-RAS(ON) Inhibitor-Based ADC Globe Newswire 7:00 AM

-- August 14, 2026 --

Adlai Nortye Ltd. Reports Unaudited First Half 2026 Financial Results and Highlights Recent Operational Progress Globe Newswire 7:00 AM

-- August 3, 2026 --

Adlai Nortye Announces Clinical Trial Notification Submission and HREC Approval for the Phase I Clinical Trial of Pan-RAS(ON) Inhibitor ADC AN4035 in Australia Globe Newswire 7:00 AM

-- July 16, 2026 --

Adlai Nortye Announces First Patient Dosed in Intermittent Weekly Dosing Arm of Global Phase 1 Trial of Pan-RAS(ON) Inhibitor AN9025 Globe Newswire 7:00 AM

-- July 13, 2026 --

Adlai Nortye Expands Scientific Advisory Board with Appointment of Two Leading Medical Oncologists Globe Newswire 7:00 AM

Market Data Delayed 15 Minutes